 |
        |
Rosemary HarryVice President, Regulatory Affairs and Quality Assurance Ms. Harry has more than 25 years’ experience in the medical device industry, including senior management positions responsible for quality assurance, regulatory affairs and clinical studies. The majority of Ms. Harry’s career has been focused on early stage companies where she also was active in corporate strategic planning, business plan development, and program management. Prior to her most recent work as a consultant to start-up companies in orthopedics, aesthetics, and pulmonary disease, Ms. Harry served as a member of the executive in residence program, and regulatory consultant, for incubation stage investments at Frazier Healthcare Ventures. During this time, she participated in the founding of Calypso Medical and Zeltiq Aesthetics, bringing concepts from intellectual property to commercialization in the fields of radiation oncology and aesthetics. Prior to joining Frazier, Ms. Harry held the position of Vice President of Regulatory and Clinical Affairs at EKOS Corporation, a start-up company developing an intravascular device for thrombolysis, and other management positions in regulatory, quality, and clinical within the industry. Ms. Harry holds a BS in biology from St. Mary’s College and a Master’s of Biomedical Engineering from the University of Miami. Return to Leadership |
 |
||||||
 |
 |
ORTHOCON® estimates that over 3.5 million patients undergoing surgeries in the United States and Europe each year could benefit from the intraoperative use of HEMASORB.
 |
|
ORTHOCON® Names David J. Hart Vice President of Business Operations
March 15, 2012 - Click to Download Canaan Partners Closes $600 Million Fund, Canaan IX January 9, 2012 - Click to Read More |
||
|
||||||
